{"id":"W4413114117","doi":"10.1002/cpdd.1583","title":"Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Infection and Immunity","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Coronavirus disease 2019 (COVID-19); Pharmacokinetics; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Virology; Monoclonal antibody; 2019-20 coronavirus outbreak; Pharmacology; Antibody; Immunology; Adverse effect; Internal medicine; Infectious disease (medical specialty); Outbreak; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009935792,0.0005009305,0.0006625095,0.0002077278,0.0002856459,0.0002336036,0.0001888349,0.0004725305,0.0008060505],"category_scores_gemma":[0.0007604354,0.0002741453,0.0005232637,0.0001922829,0.0003623677,0.000275086,0.0001489255,0.0004374872,0.0001522908],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004012754,"about_ca_system_score_gemma":0.0004520079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001747227,"about_ca_topic_score_gemma":0.002359225,"domain_scores_codex":[0.9996228,0.0001560407,0.00002411044,0.00006072774,0.00008240994,0.00005380447],"domain_scores_gemma":[0.9996803,0.0000643652,0.0001141762,0.00001707051,0.00003955574,0.00008453137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3137821,0.01278376,0.2068051,0.001280009,0.002041908,0.001064554,0.001364104,0.001919195,0.218081,0.0001693285,0.00165802,0.2390511],"study_design_scores_gemma":[0.03509086,0.3625876,0.5790669,0.00003985972,0.00168971,0.0007611538,0.0002779601,0.002130089,0.0161948,0.00009886284,0.001994343,0.00006773244],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9990634,0.0004978224,0.00008415202,0.00002965502,0.000005859703,0.00006830519,0.0000634519,0.000005915143,0.0001814516],"genre_scores_gemma":[0.9992052,0.0002542259,0.0001332771,0.00008480126,0.00002251446,0.00005997377,0.00008181791,0.000001395798,0.0001568644],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001747227,"threshold_uncertainty_score":0.005254626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05256922252441759,"score_gpt":0.4732816387254207,"score_spread":0.4207124162010031,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}